Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6041)	3/27/2002 9:29:48 AM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

The WSJ picked up the Milrinone story this morning saying that the drug has minimal effectiveness and some serious side effects...

To: Biomaven who wrote (6041)	4/4/2002 12:56:03 PM
From: sammaster	Respond to of 52153

re: "One caution: a very savvy physician friend I know has in the past been pretty cautious about the value of Nesiritide given the entrenched and mostly cheap drugs it competes with." cost is not much of an issue once the patient actually needs hospitalization....the best, most effective, safest drugs will get used...natrecor seems to be effective and is also safer(for a variety of reasons) than the traditional milrinone/dobutamine i do think its outpatient usage may be limited however, unless a patient is discharged from the hospital on this drug for short term....